ATAI News and Press, ATAI Life Sciences N.V. From 12/15/21

• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai’...

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A nove...

RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial of RL-007 These results support the progression of RL-007 to a do...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology I...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health. This new platform company will focus on the generation of intellectual property and further strengthen atai’s ...

Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improvin...

atai Life Sciences (NASDAQ:ATAI) increased its ownership interest in COMPASS Pathways from 19.4% to 20.8% indicating the potential of COMP360 in mental health care, post the recent COMP360 data in treatment-resistant depression. Over 300M people worldwide live with depression and, of the...

Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021...

The obesity epidemic is still bursting at the seams. In fact, according to Medical News Today, the issue contributes to more than five million global deaths every year. In addition, a ccording to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults...